首页|重组人促红素联合罗沙司他治疗维持性血液透析肾性贫血的效果及对铁代谢指标的影响

重组人促红素联合罗沙司他治疗维持性血液透析肾性贫血的效果及对铁代谢指标的影响

扫码查看
目的 探究在维持性血液透析肾性贫血患者中采用重组人促红素联合罗沙司他治疗的效果及对铁代谢指标的影响.方法 选取 2020 年 12 月—2023 年8 月剑河县人民医院收治的 90 例维持性血液透析肾性贫血患者为研究对象,按照随机数字表法将其分为对照组和观察组,各 45 例.对照组采用重组人促红素治疗,观察组在对照组基础上联合罗沙司他治疗,两组均治疗 2 个月.对比两组的临床疗效、铁代谢指标、贫血指标、不良反应.结果 观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗前,两组各项铁代谢指标、贫血指标对比,组间差异无有统计学意义(P>0.05);治疗后,观察组血清铁蛋白、转铁蛋白饱和度、转铁蛋白、血红蛋白、红细胞计数、红细胞比容水平均高于对照组,铁调素、可溶性转铁蛋白受体水平均低于对照组,组间差异有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05).结论 在维持性血液透析肾性贫血患者中采用重组人促红素联合罗沙司他治疗可有效调节铁代谢指标及贫血指标,且安全可靠.
Effect of Recombinant Human Erythropoietin Combined with Roxadustat in the Treatment of Maintenance Hemodialysis Renal Anemia and Its Impact on Iron Metabolism Indicators
Objective To explore the efficacy of recombinant human erythropoietin combined with roxadustat in maintenance hemodialysis patients with renal anemia and its impact on iron metabolism indicators.Methods Selecting 90 patients with maintenance hemodialysis renal anemia admitted to Jianhe County People's Hospital from December 2020 to August 2023 as the research subjects,according to the random number table method,they were divided into a control group and an observation group,with 45 cases in each group.The control group received treatment with recombinant human erythropoietin,while the observation group received combined treatment with roxadustat on the basis of the control group.Both groups were treated for 2 months.The two groups'clinical efficacy,iron metabolism indicators,anemia indicators,and adverse reactions were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,the differences was statistically significant(P<0.05);before treatment,comparison of various iron metabolism indicators and anemia indicators between the two groups,there was no statistically significant differences between groups(P>0.05);after treatment,the levels of serum ferritin,transferrin saturation,transferrin,hemoglobin,red blood cell count,and hematocrit in the observation group were higher than those in the control group,while the levels of hepcidin and soluble transferrin receptor in the observation group were lower than those in the control group,the differences between groups were statistically significant(P<0.05);comparison of adverse reactions between two groups,the differences was not statistically significant(P>0.05).Conclusion The use of recombinant human erythropoietin combined with roxadustat in maintenance hemodialysis patients with renal anemia can effectively regulate iron metabolism indicators and anemia indicators,and is safe and reliable.

Maintenance hemodialysisRenal anemiaRecombinant human erythropoietinRoxadustatIron metabolism indicatorsAnemia indicators

龙金竹

展开 >

剑河县人民医院肾内科(血液净化中心),贵州黔东南 556000

维持性血液透析 肾性贫血 重组人促红素 罗沙司他 铁代谢指标 贫血指标

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(7)